Semaglutide is a GLP-1 medication that supports appetite management and metabolic health as part of a comprehensive wellness plan
"While these findings will understandably be welcomed by those living with obesity and looking for safe and effective treatments, given the recent spike in popularity related to the benefits of the GLP-1 treatment with global and high-profile celebrities commenting on its success, global demand has increased and resulted in a worldwide shortage of the drug." Prevalence of Obesity Among Cancer Patients According to the World Health Organization, 13% of adults worldwide are obese, a condition associated with an increased risk of developing cancer
Meet Your Weight Loss Doctors Recognized among Arizonas top physicians, Dr
The 19th International Congress of the Society for Melanoma Research, 2022
Medically reviewed by Missy Zammichieli, DNP, APRN, FNP-BC Updated March 2, 2026 GLP-1 Medications: What You Need to Know GLP-1 receptor agonists mimic a natural gut hormone that regulates appetite and blood sugar Semaglutide (Wegovy/Ozempic) targets GLP-1 receptors
Each mechanism targets a different part of the metabolic system, and the early evidence is that recruiting more pathways generally produces more weight loss, though at the cost of more complex pharmacology
